Lithium plus antipsychotics or anticonvulsants for bipolar disorder: Comparing clinical response and metabolic changes. (January 2023)

• Record Type: Journal Article
• Authors: Köhler-Forsberg, Ole; Sylvia, Louisa G; Thase, Michael; Calabrese, Joseph R; Tohen, Mauricio; Bowden, Charles L; McInnis, Melvin; Iosifescu, Dan V; Kocsis, James H; Friedman, Edward S; Ketter, Terence A; McElroy, Susan L; Shelton, Richard C; Fung, Vicki; Ostacher, Michael J; Nierenberg, Andrew A
• Is Part Of: Australian and New Zealand journal of psychiatry. Volume 57:Number 1(2023)
• Page Start: 93
• Page End: 103
• Publication Date: 2023-01
• Subjects: Bipolar disorder -- lithium -- antipsychotic -- anticonvulsant -- bipolar depression; Psychiatry -- Periodicals; Psychiatry -- Australia -- Periodicals; Psychiatry -- New Zealand -- Periodicals; 616.89005
• DOI: 10.1177/00048674221077619
• Languages: English
• ISSNs: 0004-8674

Abstract

Objective: Patients with bipolar disorder treated with lithium often require additional antipsychotics or anticonvulsants. However, the comparative effectiveness and safety of these agents as add-on to lithium has not been studied. Methods: This secondary analysis combined two similar 24-week trials on outpatients with bipolar disorder randomized to lithium (target serum level 0.4–0.6 mEq/L). Guideline-based adjunctive antipsychotics (Li+AP) and anticonvulsants (Li+AC) could be used if clinically indicated and was assessed at every study visit. Response was measured on the Clinical Global Impression scale and we performed adjusted mixed effects linear regression analyses. Analysis of variance tests compared metabolic measures including a binary diagnosis of metabolic syndrome before and after 24 weeks of treatment. Results: Among 379 outpatients (57% female, mean age 38 years, mean Clinical Global Impression 4.4), users of Li+AP ( N = 50, primarily quetiapine and aripiprazole) improved to a similar degree (mean Clinical Global Impression improvement = 1.6, standard deviation = 1.5) as those using lithium-only (i.e. without adjunctive antipsychotics or anticonvulsants, N = 149, mean Clinical Global Impression improvement = 1.7, standard deviation = 1.4) ( p = 0.59). Users of Li+AC ( N = 107, primarily lamotrigine and valproate, mean Clinical Global Impression improvement = 1.2, standard deviation = 1.3) and users of Li+AP+AC ( N = 73, mean Clinical Global Impression improvement = 1.1, standard deviation = 1.3) showed worse response compared to lithium-only users (all p < 0.01). When comparing Li+AP to Li+AC, users of Li+AP improved slightly better on general ( p = 0.05) and manic symptoms ( p = 0.01), but showed a worse development of glucose, triglycerides, and metabolic syndrome. Conclusion: Despite treatment-by-indication confounding, these findings are relevant for real-world treatment settings and emphasize the need for randomized trials on this clinically important topic.